Role of recombinant interferon alpha2 and cimetidine in patients with advanced malignant melanoma

1988 ◽  
Vol 114 (1) ◽  
pp. 108-109 ◽  
Author(s):  
Tariq I. Mughal ◽  
William A. Robinson ◽  
M. Roy Thomas ◽  
Robert Spiegel
Keyword(s):  
Malignant Melanoma ◽  
Recombinant Interferon ◽  
Advanced Malignant Melanoma

Three consecutive phase II studies of recombinant interferon alfa–2a in advanced malignant melanoma. Updated analyses

Cancer ◽  
1987 ◽  
Vol 59 (S3) ◽  
pp. 638-646 ◽  
Author(s):  
Edward T. Creagan ◽  
David L. Ahmann ◽  
Stephen Frytak ◽  
Harry J. Long ◽  
M. N. Chang ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Interferon Alfa ◽  
Recombinant Interferon ◽  
Phase Ii Studies ◽  
Advanced Malignant Melanoma ◽  
Consecutive Phase

Phase II trial of recombinant interferon-?? with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma

1995 ◽  
Vol 5 (4) ◽  
pp. 273-276 ◽  
Author(s):  
L. G. Feun ◽  
N. Savaraj ◽  
F. Moffat ◽  
D. Robinson ◽  
A. Liebmann ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recombinant Interferon ◽  
Advanced Malignant Melanoma

The Role of PET/CT in Advanced Malignant Melanoma

PET Clinics ◽  
2011 ◽  
Vol 6 (1) ◽  
pp. 27-35
Author(s):  
Imene Zerizer ◽  
Brian Ng Cheng Hin ◽  
Wing Yan Mok ◽  
Sameer Khan ◽  
Domenico Rubello ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Pet Ct ◽  
Advanced Malignant Melanoma

Phase II Study with Ifosfamide in Advanced Malignant Melanoma

1988 ◽  
Vol 74 (2) ◽  
pp. 163-165 ◽  
Author(s):  
Elena Negretti ◽  
Laura Ferrari ◽  
Valeria Bonfante ◽  
Emilio Bajetta
Keyword(s):  
Malignant Melanoma ◽  
Phase Ii ◽  
Tumor Response ◽  
Phase Ii Study ◽  
Dose Schedule ◽  
Metastatic Malignant Melanoma ◽  
Advanced Malignant Melanoma ◽  
Previously Treated ◽  
The Given

Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma. The drug was administered at the dose of 3 g/m2 on days one and two every 3-weeks. Seven patients were not previously treated and 5 received only minimal prior chemotherapy. Visceral involvement was present in 9 patients, and the remaining 3 had only soft tissue lesions. No patient showed objective tumor response. Mild vomiting was observed in 75% of patients; alopecia occurred in all of them. No other major side effects were observed, in particular, myelotoxicity and urotoxicity. Lack of response advised us to discontinue patient accrual. Our data do not support a therapeutic role of ifosfamide at the given dose schedule in the treatment of metastatic malignant melanoma.

Sign in / Sign up

Export Citation Format

Share Document